Fertility Medication Billing: Gonal-F, Menopur, Follistim J-Codes

Billing fertility medications — gonadotropins for ovarian stimulation, GnRH agonists and antagonists for cycle control, human chorionic gonadotropin triggers, and progesterone for luteal phase support — is one of the most technically demanding segments of the fertility revenue cycle. Unlike surgical procedures, where a CPT code is submitted against a diagnosis and adjudicated within a predictable framework, fertility drug claims can route to a patient's medical benefit, their pharmacy benefit, a specialty fertility benefit manager's formulary, or a third-party specialty pharmacy that bypasses the clinical practice entirely. The same drug — Gonal-F 450 IU — billed by a practice that dispenses in-office under a buy-and-bill arrangement follows a completely different pathway, with different J-codes, different NDC documentation requirements, and different authorization logic, than the same drug prescribed by the same physician and dispensed by a contracted specialty pharmacy shipped directly to the patient's home. Billing teams that lack a structured fertility drug billing protocol routinely produce two categories of preventable revenue loss: unreimbursed drug costs on medications the practice dispenses in-office but fails to bill correctly, and denial cascades on pharmacy-benefit drug claims driven by incorrect benefit routing, wrong J-code selection, missing NDC numbers, or expired prior authorizations. This guide addresses both categories with the specificity required to operationalize correct drug billing across your fertility practice.

Benefit Routing: Medical Benefit vs. Pharmacy Benefit

Before a single J-code is selected, the billing team must answer one question for every fertility drug dispensing event: is the drug being dispensed by the practice — physically administered in-office or dispensed from the practice's own medication inventory — or is it being prescribed to the patient, filled at a specialty pharmacy, and delivered directly to the patient's home? That routing question determines the entire billing pathway, the submission channel, the required documentation, and the adjudication outcome.

When a practice operates a buy-and-bill arrangement — purchasing drugs at wholesale cost, storing them in-office, dispensing them directly to the patient, and billing the payer for the drug supply using J-codes on a CMS-1500 medical claim — the drug claim is submitted under the physician's NPI, identified by its assigned J-code, and must include a National Drug Code in the NDC qualifier field on every drug claim line. Practices that submit J-code drug claims without the required NDC number face systematic denial from commercial payers that require NDC documentation for all drug supply claim lines, regardless of the specificity of the J-code itself. When the practice prescribes the drug and the patient fills it at a specialty pharmacy, the practice does not bill for the drug at all. The specialty pharmacy bills the patient's pharmacy benefit directly using the drug's NDC number through the pharmacy benefit channel. The fertility practice's only billing activity for that medication event is the encounter visit at which the prescription was written — an office E&M code, not a drug supply code. Practices that incorrectly duplicate drug billing — submitting a J-code on the medical claim for a drug the specialty pharmacy already dispensed and billed — create overpayment exposure that results in full recoupment when the duplication is identified during post-payment audit.

J-Codes for Fertility Medications: Complete Reference Table

The following J-codes govern the major injectable and physician-supplied medications used in fertility stimulation cycles and ART cycle support. All are billed on the CMS-1500 under the medical benefit when the practice dispenses in-office. Each requires an NDC number attached to the claim line in the N4 qualifier format, and each requires a diagnosis code establishing the medical necessity of the drug on the same claim. The dosage unit for gonadotropin codes must be calculated precisely from the IU or mg dispensed on that date — the table notes the calculation method for each code.

Calculating Billing Units for Gonadotropin J-Codes

The most consequential unit-calculation error in fertility drug billing involves the per-75-IU coding unit that governs J1575 (Gonal-F), J1572 (Follistim AQ), and J1060 (Menopur). Each dispensing event must be translated into the correct number of billing units by dividing the total IU dispensed on that date by 75. A patient who receives Gonal-F 450 IU on a single dispensing date has received 6 billing units of J1575 (450 ÷ 75 = 6). A patient who receives 225 IU of Menopur receives 3 billing units of J1060 (225 ÷ 75 = 3). A practice whose billing software defaults every gonadotropin claim line to 1 unit — regardless of the actual IU dispensed — is capturing a fraction of the correct drug reimbursement on every single in-office dispensing event, compounded across every cycle and every patient throughout the year. This error is common, systematic, and frequently goes undetected for months because the claims pay at a reduced amount rather than denying outright.

When the total IU dispensed is not evenly divisible by 75, round up to the nearest whole unit and document the rounding basis in the billing notes. The correct quantity is always: total IU dispensed ÷ 75, rounded up to the next whole unit. Document the total IU dispensed in the clinical note at the time of dispensing so the billing team can calculate units directly from the chart rather than estimating from the original prescription order, which may differ from what was actually dispensed if the physician adjusted the dose. For progesterone in oil (J2675), the billing unit is per 50 mg: a 100 mg IM injection equals 2 units, a 200 mg injection equals 4 units. For leuprolide acetate (J1950), the unit is per 3.75 mg: a standard 7.5 mg monthly injection equals 2 units. For Ovidrel (J0709), the standard 250 mcg prefilled syringe equals 0.5 billing units per the code definition — confirm with each payer whether they round to 1 unit per syringe and apply that rule consistently across all Ovidrel claim lines for that payer.

Prior Authorization Requirements for Gonadotropins

Every major commercial payer — Aetna, Cigna, BCBS affiliates, UHC, and their self-funded plan TPA networks — requires prior authorization for gonadotropins under both the medical and pharmacy benefit. The authorization is payer-specific, benefit-specific, and drug-specific. An authorization approved for Gonal-F under the pharmacy benefit does not cover Gonal-F billed as J1575 under the medical benefit — these are treated as separate authorization requests by most payers, even when the same drug is prescribed by the same physician for the same patient. A PA obtained through the specialty pharmacy for home delivery does not cover in-office dispensing, and vice versa. The authorization pathway must match the dispensing channel before the first dose is administered. The following documentation is typically required in the initial PA submission package:

• Infertility diagnosis documented in the chart and supported by a specific ICD-10 code tied to the clinical etiology: N97.0 for anovulatory infertility, N97.1 for tubal factor infertility, N97.2 for infertility due to uterine anomaly, N97.8 for other specified female infertility, N97.9 for female infertility unspecified when etiology is under active investigation, or N46.x codes for male factor infertility when stimulation is being performed for that indication — do not default to N97.9 when a more specific code is supported by the clinical record
• Duration of infertility meeting the payer's time threshold: 12 months of documented unprotected intercourse for patients under age 35, 6 months for patients 35 and older, or an exception pathway for patients with clinical findings that remove the time requirement — bilateral tubal occlusion, premature ovarian insufficiency (E28.39), documented severe male factor infertility (N46.x), or same-sex couples where timed intercourse is not clinically applicable and the payer has an alternative documentation pathway
• Prior treatment history demonstrating step therapy compliance for payers that require it: for IUI-indication gonadotropins, most commercial plans require documentation that oral ovulation induction agents (clomiphene citrate or letrozole) were tried and failed — provide cycle dates, drugs used, doses, and clinical outcome or failure documentation for each prior ovulation induction attempt
• Baseline laboratory values confirming appropriateness for gonadotropin stimulation: Day 3 FSH and estradiol, anti-Müllerian hormone level within 12 months, and antral follicle count from a recent transvaginal ultrasound — payers vary on recency requirements from 6 to 24 months; verify the specific payer's recency window before assuming older values will satisfy the requirement
• Physician attestation documenting the intended treatment protocol (IVF, IUI, or medicated cycle type), the specific stimulation agent requested and the rationale for drug selection, the anticipated total cycle duration and estimated total IU, and — for payers that track lifetime cycle maximums — the patient's documented prior cycle count within the plan's benefit period
• Prior authorization number recorded in the practice's PA log and placed in field 23 of the CMS-1500 on every drug claim line submitted for that authorized treatment episode — a claim submitted without the PA number in field 23 is denied for "no authorization on file" even when the authorization is active and fully documented in the payer's system

Step Therapy Requirements and How They Affect Drug Authorization

Step therapy is enforced by most commercial payers for patients who have not previously undergone gonadotropin stimulation for IUI indications. Aetna's standard commercial plans typically require documentation of failed oral ovulation induction with clomiphene or letrozole before approving FSH injectables for IUI cycles. UHC commercial plans may require two to three timed intercourse or IUI cycles with oral agents before approving Gonal-F or Follistim for IUI indications. BCBS plan step therapy requirements vary significantly by state affiliate — some require step therapy for IUI-indication gonadotropins but waive it for IVF when the patient meets clinical necessity criteria without prior treatment attempts. For IVF cycles in states with legislatively mandated fertility coverage, step therapy requirements for gonadotropins are generally waived once the patient's infertility diagnosis is confirmed and IVF medical necessity criteria are met — but plan documents for self-funded employer plans, which are not subject to state mandates, may still impose step therapy regardless of state. The critical billing implication of step therapy is that submitting a gonadotropin PA request without the required prior treatment documentation produces a denial that delays the treatment cycle, forces a peer-to-peer review or appeal, and creates a gap in the prior authorization timeline that can cause downstream claim denials if the PA is ultimately issued with a start date later than the actual administration date. Build the step therapy documentation check into the PA workflow initiation step — collect prior treatment cycle records before submitting the PA request, not in response to a payer request after an initial denial.

Payer-Specific Drug Routing and Coverage Rules

Understanding which benefit handles gonadotropins for each high-volume payer in your network is the single most impactful knowledge gap a fertility billing team can close. Routing a drug claim to the wrong benefit — the medical benefit when the pharmacy benefit applies, or the FBM portal when the drug routes to the commercial carrier — produces denials that require manual rerouting, delay reimbursement by full processing cycles, and in worst cases generate overpayments when both channels pay before one payment is identified and reversed. The following rules apply to the major payer categories encountered in fertility practice billing:

• Aetna (standard commercial): Gonadotropins for IVF and IUI stimulation typically adjudicate under the pharmacy benefit through a contracted specialty pharmacy network. In-office buy-and-bill billing using J-codes under the medical benefit is not covered under most standard Aetna commercial plan designs — practices submitting J1575 or J1572 on a CMS-1500 for Aetna commercial members will receive denials citing pharmacy benefit applicability. Aetna Fertility — their specialty fertility benefit layer available on some employer plans — may have different drug channel arrangements; confirm the specific plan's drug dispensing pathway with Aetna Fertility provider relations before authorizing in-office dispensing.
• Cigna (standard commercial and Cigna Fertility): Cigna routes most injectable gonadotropins to the pharmacy benefit under their specialty drug formulary. In-office dispensing with medical benefit J-code billing is not supported under most Cigna commercial plan designs. Cigna's specialty pharmacy network handles dispensing for the majority of gonadotropin products. Cigna Fertility — available through Cigna for employers who elect the fertility benefit add-on — manages authorization, cycle administration, and specialty pharmacy coordination as an integrated benefit; drug authorization requests should be directed to Cigna Fertility specifically, not through standard Cigna medical prior authorization channels where fertility drug requests may not be recognized.
• UHC and OptumRx: UHC routes gonadotropins to the pharmacy benefit managed through OptumRx specialty pharmacy for most commercial members. The OptumRx specialty pharmacy fills and ships gonadotropins directly to the patient under the pharmacy benefit. UHC Fertility — available as a fertility benefit add-on on some UHC commercial employer plans — includes integrated authorization management and specialty pharmacy coordination; drug PA requests for patients with UHC Fertility coverage should go to UHC Fertility, not through the standard UHC medical authorization line. Attempts to bill Follistim or Menopur as J-codes on the medical claim for standard UHC commercial members will be denied as pharmacy benefit items.
• Progyny Smart Cycle participants: Medications are explicitly excluded from Progyny Smart Cycle reimbursement under the standard Progyny benefit structure. Progyny members access gonadotropins through Progyny's integrated specialty pharmacy service. The practice does not bill for medications for Progyny-covered patients — the pharmacy service manages dispensing and billing separately. Submitting J-codes to Progyny for medications the specialty pharmacy dispensed creates a duplicate billing situation. Confirm the medication dispensing channel in writing with Progyny provider relations during credentialing and verify that any new employer plan configurations are consistent with the standard channel before the first medication is dispensed.
• WINFertility network practices: WIN excludes medications from cycle reimbursement on most employer plan configurations. Medications typically route to the underlying commercial carrier's pharmacy benefit or through WIN's specialty pharmacy arrangement, which varies by the specific employer contract configuration. Contact WIN provider relations for each high-volume employer plan to confirm the medication dispensing and billing pathway — do not assume that the same channel applies across all WIN-covered patients, as employer plans configure the WIN benefit differently.
• Self-funded ERISA plans administered by a TPA: Drug coverage rules are governed entirely by the plan document — state insurance mandates regarding fertility treatment do not apply to self-funded employer plans under federal ERISA preemption. Some self-funded plans provide comprehensive gonadotropin pharmacy coverage; others impose per-cycle drug dollar maximums, restrict covered brands to a specific formulary list, or require a specific specialty pharmacy channel that differs from the practice's preferred pharmacy. Verify gonadotropin coverage explicitly during benefits investigation — not just general infertility or ART coverage — before ordering the first medication. Out-of-pocket gonadotropin costs per IVF cycle commonly range from $3,000 to $7,000 when pharmacy benefit limits are reached or benefits are exhausted mid-cycle, and the financial consent discussion with the patient must precede the prescription.

ICD-10 Diagnosis Codes for Fertility Drug Claims

Drug claims submitted on a CMS-1500 under the medical benefit require at least one ICD-10 diagnosis code that establishes the medical necessity of the drug. The code must match the clinical indication for the drug as documented in the physician's order and the chart note — not simply reflect that the patient is undergoing an ART cycle. Submitting Z31.83 (encounter for assisted reproductive fertility procedure status) as the sole diagnosis on a gonadotropin drug claim understates the medical necessity framework. Z31.83 is a procedure status code; it documents that an ART procedure is occurring but does not establish why the drug is clinically required. Payers adjudicating drug claims under the medical benefit use the primary diagnosis to determine whether the drug's indication is covered under the active benefit, and Z31.83 standing alone often fails that adjudication test.

For controlled ovarian stimulation medications (J1575, J1572, J1060, J1573): the infertility diagnosis drives the primary ICD-10 code — N97.0 for anovulatory infertility, N97.1 for tubal factor, N97.2 for uterine anomaly, N97.8 for other specified female infertility, or the appropriate N46.x code when stimulation is being performed for male factor infertility. Add Z31.83 as a secondary code to document the ART cycle context. For GnRH agonists (J1950, leuprolide): when prescribed for pituitary suppression during IVF preparation, use the infertility diagnosis as primary with Z31.83 secondary. When prescribed for endometriosis suppression outside an active ART cycle, the primary code is N80.x — N80.0 for endometriosis of uterus, N80.1 for endometriosis of ovary, N80.3 for endometriosis of pelvic peritoneum — and a fertility diagnosis code is not appropriate as primary. For hCG trigger medications (J0709, J0725): use the same infertility primary diagnosis as the stimulation cycle claim for that date, with Z31.83 secondary, maintaining ICD-10 consistency between the drug claim and the monitoring service claim for the same date. For progesterone in oil (J2675) in the IVF context: N97.x primary, Z31.83 secondary. When prescribed for luteal phase support in a recurrent pregnancy loss patient outside of ART, consider N96 (recurrent pregnancy loss) as primary with the appropriate secondary codes documenting the luteal phase deficiency or RPL diagnosis.

Common Fertility Medication Billing Errors to Avoid

• Submitting 1 billing unit of a gonadotropin J-code regardless of actual IU dispensed — the most widespread and financially significant fertility drug billing error; a practice dispensing Gonal-F 450 IU and billing 1 unit of J1575 instead of 6 units captures 17 cents on the dollar for the drug supply; multiply dispensed IU by the per-75-IU denominator on every gonadotropin claim line, every time
• Submitting J-codes under the medical benefit for drugs the specialty pharmacy dispensed — creates a duplicate claim that generates an overpayment when the duplication is identified; the pharmacy's pharmacy-benefit claim and the practice's medical-benefit J-code claim are the same drug billed twice; the practice does not bill for drugs it did not dispense
• Missing NDC numbers on J-code drug claim lines — the most common technical cause of drug claim denials under medical benefit billing; every J-code drug line requires the N4 qualifier plus 11-digit zero-padded NDC; denials for missing NDC are frequently mislabeled on the EOB as generic data errors rather than drug-specific coding errors
• Submitting the 10-digit as-labeled NDC instead of the 11-digit zero-padded 11-digit format — the label on a vial may display the NDC in 5-4-1, 5-3-2, or 4-4-2 segment format; the CMS-1500 requires the 11-digit standard format with a leading zero inserted in the shortest segment; incorrect NDC formatting causes systematic claim rejections that look like form errors on the EOB
• Using J3490 (unclassified injectable drug) for brand-name gonadotropins that have specific assigned J-codes — Gonal-F (J1575), Follistim (J1572), and Menopur (J1060) all have specific HCPCS codes; submitting them under J3490 routes claims to manual review, delays adjudication by weeks, and signals coding inaccuracy that may attract audit scrutiny of other claim categories
• Billing J3355 (Bravelle/urofollitropin) after the product's 2018 market withdrawal — Ferring discontinued Bravelle in the United States in 2018; any urofollitropin product dispensed after that date is a compounded product without a specific J-code and must be billed under J3490 with full drug description, concentration, dose, and NDC in the notes field
• Omitting the prior authorization number from field 23 of the CMS-1500 on drug claim lines — even when an active authorization exists in the payer's system, a drug claim without the PA number in field 23 is denied for "no authorization on file"; build the PA number into the claim generation workflow at the point of claim creation, not as a manual entry during pre-submission review
• Routing gonadotropin drug claims to Progyny or WINFertility when medications are explicitly excluded from their cycle reimbursement structure and should be submitted to the underlying commercial carrier's pharmacy benefit — misdirected drug claims generate immediate denials, require manual rerouting, and delay drug cost reimbursement by the full rerouting processing cycle

Documentation Requirements for In-Office Drug Dispensing

In-office drug dispensing that generates J-code billing under the medical benefit must be supported by a contemporaneous dispensing record in the patient's chart for every dispensing event. The dispensing record must include: the drug name and brand, the total IU or mg dispensed on that date, the lot number and expiration date of the specific drug lot dispensed (required for drug supply chain traceability and payer audit response), the NPI of the dispensing provider, the date of dispensing, and the patient's signed acknowledgment of receipt. Practices that bill J-codes for drugs without maintaining a formal dispensing log are exposed during post-payment audit — a payer finding that J-codes were submitted without corresponding dispensing records in the chart results in full recoupment of all drug claim payments within the audit review period, with interest assessed on the overpayment amount, and typically triggers a broader audit of other claim types in the practice's billing record.

The NDC number from the specific drug lot dispensed must be captured at the time of dispensing and recorded in the dispensing log before the drug is handed to the patient. NDC numbers are lot-specific: the NDC on a Gonal-F 900 IU pen from one manufacturing lot may differ from a pen from a different lot even within the same product and strength. Pulling the NDC from a drug catalog or reference database — rather than from the actual drug label at the point of dispensing — is technically inaccurate and creates audit exposure. The dispensing log is the chain of custody document linking the specific drug product to the specific patient encounter and the J-code claim line. If an auditor requests documentation supporting a J-code drug claim and the practice cannot produce a dispensing log showing the exact NDC, lot number, and dispensed quantity matching what was billed, the claim is recouped as unsupported regardless of whether the drug was actually administered. Build the dispensing log as a mandatory workflow step that cannot be bypassed — the biller should never be reconstructing NDC or dosage information from memory or estimation after the dispensing event has closed.

Managing Gonadotropin Drug Claim Denials

Gonadotropin drug claims denied under the medical benefit typically fall into a small number of identifiable categories, each with a specific resolution path. Denial for "pharmacy benefit applies" means the payer does not allow medical benefit billing for this drug and requires pharmacy channel submission — appeal is rarely successful; the correct response is to verify whether the practice has a buy-and-bill agreement with this payer and, if not, to redirect the patient to the specialty pharmacy for future cycles and not rebill the medical benefit. Denial for "no prior authorization" or "authorization required" means either the PA was not obtained before dispensing, the PA number was omitted from field 23, or the PA was obtained but expired before the service date — resolve by confirming the PA status in the payer's portal, correcting the claim with the active PA number, and resubmitting; if no PA was obtained, submit a retro-authorization request with the same clinical documentation as a prospective PA and document the clinical urgency if applicable. Denial for "invalid NDC" or "NDC required" indicates the NDC was either missing, formatted incorrectly, or does not match the J-code on the same claim line — correct the NDC to the 11-digit N4 format matching the dispensed drug lot, verify the NDC-to-J-code match, and resubmit. Denial for "non-covered service" in states with fertility insurance mandates may indicate a self-funded employer plan that is exempt from the state mandate — verify plan type through benefits investigation before pursuing an appeal on coverage grounds; appeals citing state mandate requirements have no standing against ERISA-governed self-funded plans.